ABCL
AbCellera Biologics Inc.
There isn't enough reported data to score ABCL yet.
ABCL Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Strong |
ABCL's revenue and balance sheet are currently healthy, but its profitability and cash flow are under pressure.
ABCL PE Valuation
ABCL has no meaningful PE right now: it lost money over the past year.
ABCL Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong growth | |
| -- | |
| Limited | |
| Low |
Analysts expect ABCL's losses to grow, with revenue growing. However, they disagree widely on these estimates.
ABCL Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.48 | +$0.09 |
| Q2 2026 | -$0.54 | +$0.01 |
| Q1 2026 | -$0.48 | +$0.08 |
| Q4 2025 | -$0.49 | +$0.06 |
| Q3 2025 | -$0.57 | +$0.03 |
| Q2 2025 | -$0.55 | -$0.02 |
| Q1 2025 | -$0.56 | -$0.05 |
| Q4 2024 | -$0.55 | -$0.04 |
ABCL is still losing money, but less than at its worst: $0.48 per share over the past year, against $0.60 at its worst in late 2024.
ABCL Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $10.6M | +19% |
| Q2 2026 | $4.1M | -76% |
| Q1 2026 | $8.3M | +96% |
| Q4 2025 | $44.9M | +788% |
| Q3 2025 | $9M | +38% |
| Q2 2025 | $17.1M | +133% |
| Q1 2025 | $4.2M | -57% |
| Q4 2024 | $5.1M | -45% |
ABCL's revenue is recovering but still below its 2022 peak: $11M last quarter, up 19% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -501% | +351 points |
| Q2 2026 | -1550% | -1260 points |
| Q1 2026 | -692% | +788 points |
| Q4 2025 | -64% | +1377 points |
| Q3 2025 | -852% | +588 points |
| Q2 2025 | -290% | +986 points |
| Q1 2025 | -1480% | -928 points |
| Q4 2024 | -1441% | -721 points |
ABCL's operating margin was −501% last quarter, up 351 points from the same quarter a year ago.
ABCL Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $25.3M | +$86.8M |
| Q2 2026 | $23.8M | +$69.6M |
| Q1 2026 | -$37.4M | -$15.2M |
| Q4 2025 | -$44.6M | -$21M |
| Q3 2025 | -$61.5M | -$14.1M |
| Q2 2025 | -$45.8M | +$4.3M |
| Q1 2025 | -$22.2M | +$43.7M |
| Q4 2024 | -$23.6M | +$10.4M |
ABCL has burned cash in most quarters: −$33M over the past year, against −$153M the year before.
ABCL Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.1% | +12.5M shares |
| 1 year | +6.4% | +19.2M shares |
| 3 years | +9.9% | +28.6M shares |
| 5 years | +14% | +39.1M shares |
| Available history | +34% | +80.3M shares |
ABCL has 318M diluted shares, up 6.4% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
| Q4 2019 | — |
ABCL Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2022 | -1.6x | Net Cash |
| Q3 2022 | -1.1x | Net Cash |
| Q2 2022 | -2.8x | Net Cash |
| Q1 2022 | -1.9x | Net Cash |
| Q4 2021 | -2.2x | Net Cash |
| Q4 2020 | -3.5x | Net Cash |
| Q3 2020 | -12.0x | Net Cash |
| Q2 2020 | -14.9x | Net Cash |
ABCL has more cash than debt.
ABCL Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 61.4 | Neutral |
| Stochastic | 62.7 | Neutral |
ABCL's weekly RSI is 61 (neutral) and its Stochastic is 63 (neutral).
ABCL PE vs Healthcare Sector
| Metric | ABCL | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ABCL has no meaningful PE right now: it lost money over the past year.
ABCL Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $12.3 | 5.5% below |
| 20 week MA | $10.3 | 12% above |
| 50 week MA | $6.63 | 75% above |
| 100 week MA | $5.07 | 129% above |
| 200 week MA | $5.06 | 130% above |
ABCL's trend is up, with a small recent dip: it's below only its 8-week average, and 130% above its 200-week average.
ABCL Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $58.9 | $42.4 | -28% |
| 2021 | $42.4 | $14.9 | -65% |
| 2022 | $14.9 | $10.3 | -31% |
| 2023 | $10.3 | $5.71 | -45% |
| 2024 | $5.71 | $2.99 | -48% |
| 2025 | $2.99 | $3.58 | +20% |
| 2026 YTD | $3.58 | $11.6 | +225% |
ABCL is up 225% so far in 2026, after finishing lower in five of the previous six years.